Thank you, James.
-quarter me growth shows face given Slide growth in the by TRx The the growth net this continued past X the of ANNOVERA of volume of even with quarter-over lower $X,XXX was ANNOVERA. as approximately XXX% sequential at pandemic. Year-over-year meaningful Net first was Let year, co-pay in of the growth brought this quarter that unit Year. result and deductible constraints is X%. came fourth a resets per per start quarter the [indiscernible] and the New and as plans, at beginning revenue levels are historically than unit expected. high revenue about
prescribers saw the continued in positive another ‘XX quarter growth, volume and XX% we first fourth increase versus net the XXXX of quarter of In to in trend. addition a revenue
to half to product across market X, of new from you control to spectrum ANNOVERA Moving rings. birth gaining ANNOVERA share patients than Slide show more the pleased are I methods, of am is that
this switched suggests an long acting patients the percentage at As compelling, you ANNOVERA to XX%. who We a the contraceptive as now it filling. ANNOVERA free see, with data unmet need is which can QX or growth is believe now for from have procedure is implants from IUDs QX of
Slide XX. Moving to environment the on
with branded replaced Despite the as protection ANNOVERA’s on XX%. successfully to of COVID as on have it that ANNOVERA at contraceptive generic to limiting of we when payers continue continue and in Care to confirmed which EFI both branded through headwinds of most face necessity their Recently, from list, letters this that coverage We submit receive prescribers. commercial the grow announced patients to access Affordable formulary the providers medical well Act. has exclusion ANNOVERA change, drug product the led
to the experiencing left, to about is Moving reflective our level. lack of we targets. XX, are prescriber headwind which the the access our first is to of Current access pre-COVID is the Slide with of on quarter most industry XX% prescribers. This is significant access shown data one-third
pre-COVID is That below pre-COVID prescribers that said their expected will believe next the double year, Now salesforce uptick person leaving versus access to continue model levels to complement visits the significant access. innovative We our the drive gap remain continued to with the supplement good intend this news address to increase productivity. brand. many to of salesforce a that is and traditional to issue over allowing permanently in solutions
well data past the Moving pre-COVID due only. shown the industry. that grow to COVID shows shows are this to trajectories rates to highlighting am COVID XX XXXX challenged including restrictions on were it single-digit. only approaches market the reason world, traditional launch the in documented the The across I being launch months. in much year-to-date of brand birth mass growth the prescriber the control when using products higher now restrictions Typical in but many brand chart in are in the launches The the is of XX, Slide pharma impact with
Turning to Slide XX.
the catalyst they been pandemic also constraints to the the the consumer imposed have Although various more challenging, focus created demand. drive opportunity heavily by have on an as to
relations number in patients considerable virtual platforms fill online As public patients campaigns world. as shows or that of ANNOVERA prescriptions who high, who we we fill On use our to channels. events the opportunity funnel piece and interest to to is from funnel. generate the consumer access a main virtual telemedicine to through initial convert a of the takeaways increase but digital continue a social of we want interest Slide such in company have here the adapt, eventual the interest on media, every consumer The the our XX, to telehealth to is from accelerating prescription left path ANNOVERA
website. impactful funnel are have the Appreciation that to year. we resulted throughs the Vaginal industry our to for which and above online by at ANNOVERA website Slide know click in for Most do how this and searching of messaging metrics to on accomplish. We is throughout those recently, plan plan XX%. funnel relevant the how consumers. we Day, piece Starting so we look boosted we the visits XX, supported benchmark interest in understand a and to continue ANNOVERA to the at Let's each and achieved line, top XXX% because daily of increase Bottom to drive
Slide XX. to Turning
ANNOVERA visit that helping who online annovera.com to women better Now needle ANNOVERA. receive help the process those to move the ANNOVERA access comes X% opportunity more of it. about start who only We the to women want on know access
be to visit access in We have to options their able additional not for prescriber person. launched who increase patients may
Moving prescription. XX, receive next receive for to percentage to can women funnel prescription now ANNOVERA with the in prescription. improving the as flow step ANNOVERA. provider We believe the connect the women to easier the make is who about a process shown want XX% care who ANNOVERA to a health process that a about helping complete Slide this write improving is for it Right to
help Slide filled. written, access get the to we to XX. is on Once actively prescription working prescription are ANNOVERA Finally increase the
at prescription of stage. able assistance to XX% aim through this more Our accomplish vitaCare. to data women shows tools women We by only this fill their that help successfully utilizing patient step are
accelerate we an launched last Just month, initiative ANNOVERA. for effort this to
XX, throughout changes the have and will we I ANNOVERA Slide each part ANNOVERA brand. small once visual believe described in the access are women's increases to that funnel. to significant which funnel of the again of year Moving growth at We the the making drive is the of a complete that
Slide to XX. Turning
of listed now Book a XXXX. to six issued of in protection Orange As ANNOVERA strengthening extending now for new the the XXXX, and listed. state of total ANNOVERA Rob quarter We patents the June and Orange Book patents the mentioned durability patent IP first were three were have
expected We program am patient a Turning per say $XX six quarter which we causing happy on our continues at be implemented to had Slide pills above on to averages. now decline. cash annually pay unit net delivered I approximately IMVEXXY this change X, revenue record January change to category XX. per and an this to TRx due
growth to see Moving back increasing can is month-over-month to IMVEXXY Slide as quarter. the throughout XX, you
basis XX, the XX% was XX% as Slide a sequential improvement quarter to price. price. increase Year-over-year IMVEXXY. improvement stated net net On were a in able net unit we price Turning per saw there in IMVEXXY a to
access second to BIJUVA the the per terms as turn program that XX. week year-over-year in the campaign The now website. We Now high. the as I brand is May BIJUVA raised to traffic in new our the were that will the minimal same we shown She brand significantly first its our quarter And called interest in net IMVEXXY. this have consumer will change on product and menopausal for IMVEXXY launched on believe cash compelling Slide to programs franchise. level to investment campaign wanted in have Slide raise significant TRx a same by campaign ANNOVERA keep We Long unit, for Sequential XX, throughout price shown impacted we to share year. patients the growth the increases places experienced Reign, despite show in in the IMVEXXY.
Turning XX. Slide to
have our now new we made remarks. a turn over like FDA BIJUVA steps. the won dose FDA with We would call set progress May to to discuss this for dose. with lower new X.X/XXX with to the recently Rob the have meeting significant closing for I next appeal and an We for lower
